Recursion Pharmaceuticals Inc (RXRX)
Guardado en:
| Publicado en: | GlobalData Financial Profiles (2025) |
|---|---|
| Publicado: |
GlobalData plc
|
| Materias: | |
| Acceso en línea: | Citation/Abstract Full Text - PDF |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Resumen: | Recursion Pharmaceuticals Inc (RXRX) - Financial Analysis Review Recursion Pharmaceuticals Inc (Recursion) is a clinical-stage biotech company. It harnesses the Recursion Operating System (OS) technology platform to develop drugs. The company has a pipeline of internally developed clinical and preclinical programs for precision oncology and genetically induced rare diseases with unmet medical need. GlobalData's Recursion Pharmaceuticals Inc (RXRX) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years. Recursion Pharmaceuticals Inc Key Recent Developments: May 05,2025: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update Apr 09,2025: Recursion and Enamine Unveil New AI-Enabled Targeted Compound Libraries Apr 01,2025: Recursion to Participate in Upcoming Investor Conference Mar 18,2025: Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. |
|---|---|
| Fuente: | ABI/INFORM Trade & Industry |